UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.

Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Study Group.SourceISTA PharmaceuticalsR Inc., Irvine, CA 92618-2301, USA. jwilliams@istavision.com
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.J Ocul Pharmacol Ther.2011 Aug;27(4):385-93. Epub 2011 Jun 7.
PURPOSE: This clinical trial evaluated the safety and effectiveness of bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo for the treatment of ocular itching and conjunctival hyperemia (redness) using the conjunctival allergen challenge (CAC) model of allergic conjunctivit
PMID 21649522

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.

Wingard JB, Mah FS.SourceUPMC Eye Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Clinical ophthalmology (Auckland, N.Z.).Clin Ophthalmol.2011;5:201-7. Epub 2011 Feb 15.
Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This re
PMID 21386912

大森睦美,竹内聡,田代あかり,中原剛志,三苫千景,寺尾浩,浦田保志,吉村映里,工藤恭子,安川晋輔,辻田淳,国場尚志,増永可奈,桑原健太郎,市川竜太郎,伊藤絵里子,竹下弘道,安川史子,西江温子,師井洋一,古江増隆
西日本皮膚科 = The Nishinihon journal of dermatology 72(3), 240-245, 2010-06-01
NAID 10026929692